Skip to main content Skip to main navigation menu Skip to site footer

Extracutaneous manifestations of adult psoriatic patients attending Dermatology Teaching Center in Slemani, Iraq



Abstract

Background: Psoriasis is debilitating, albeit remained underdiagnosed and undertreated, disease typically known for its cutaneous manifestations. Recent evidence pointed towards multisystemic comorbidities that we aim to elucidate further in this study.

Methods: A cross-sectional descriptive study was conducted in Dermatology Teaching Center in Slemani city from April to September 2019. One hundred dermatologist-confirmed psoriasis patients aged 18 years old and above were subjected to structured interview, physical examination and blood investigations to determine the presence of psoriasis extracutaneous manifestations.

Results: There were a total of 100 patients with a mean age of 47.2 ± 15. Majority of the patients comprised of middle age group (42.0%), female (67.0%), with 10-20 years disease duration (36.0%). Only a few of them are currently smoking (16.0%) and consume alcohol (6.0%). Patients with extracutaneous involvement primarily had multiple (37.0%) as opposed to singular (24.0%). Metabolic syndrome was the most prevalent (30.0%) extracutaneous manifestation in this study.

Conclusions: Extracutaneous manifestations of psoriasis were ubiquitous and often coexisted. Emerging progressive comorbidities prompted greater recognition and integrated multidisciplinary approach.

Keywords: Psoriasis Extracutaneous Comorbidities Prevalence

References

  1. Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi:10.1101/cshperspect.a015354.
  2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology. 2017;31(2):205-12. doi: 10.1111/jdv.13854.
  3. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology. 2013;133(2):377-85. doi: 10.1038/jid.2012.339.
  4. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278–285. PMID: 28404701.
  5. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi:10.1590/abd1806-4841.20153038.
  6. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058.
  7. Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi:10.1111/dth.12589.
  8. Duarte GV, Oliveira MF, Follador I, Silva TS, Carvalho EM Filho. Diagnosis and underdiagnosis of comorbidities in psoriasis patients - need for a multidisciplinary approach. An Bras Dermatol. 2016;91(6):743–747. doi:10.1590/abd1806-4841.20164716.
  9. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991 Aug;30(4):245-50. doi: 10.1093/rheumatology/30.4.245.
  10. Feldman SR, Zhao Y, Shi L, Tran MH, Lu J. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken). 2015;67(5):708–717. doi:10.1002/acr.22492.
  11. Owczarek K, Jaworski M. Quality of life and severity of skin changes in the dynamics of psoriasis. Postepy Dermatol Alergol. 2016;33(2):102–108. doi:10.5114/pdia.2015.54873.
  12. Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196-203. doi: 10.1080/13696998.2018.1557201.
  13. Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332-1343. doi: 10.1016/j.jaad.2018.12.037.
  14. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3(1):19–62. doi:10.1038/kisup.2012.64.
  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52. doi: 10.1161/CIRCULATIONAHA.105.169404.
  16. Centers for Disease Control and Prevention. (2017). National Health Interview Survey - Adult tobacco use information - Glossary. [online] Available at: https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm [Accessed 4 Mar. 2020].
  17. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015–2020 Dietary guidelines for Americans. 8th Edition. December 2015. Available at http://health.gov/dietaryguidelines/2015/guidelines/.
  18. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119–132. doi:10.2147/CCID.S44843.
  19. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010;23(2):114-8. doi: 10.1111/j.1529-8019.2010.01304.x.
  20. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-28. doi: 10.1016/j.clindermatol.2017.09.005.
  21. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064.
  22. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568. doi:10.1016/j.rdc.2015.07.001.
  23. Binus AM, Han J, Qamar AA, Mody EA, Holt EW, Qureshi AA. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26(5):644-50. doi: 10.1111/j.1468-3083.2011.04153.x.
  24. Carvalho AV, Romiti R, Souza CD, Paschoal RS, Milman LM, Meneghello LP. Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol. 2016;91(6):781–789. doi:10.1590/abd1806-4841.20165080.
  25. Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012 May;11(5 Suppl):s5-10.
  26. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. doi:10.1161/JAHA.113.000062
  27. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2009;11(12):761–765. doi:10.1111/j.1559-4572.2009.00054.x.
  28. González-Parra E, Daudén E, Carrascosa JM, Olveira A, Botella R, Bonanad C, et al. Kidney disease and psoriasis. A new comorbidity? Actas Dermosifiliogr. 2016;107(10):823-829. doi: 10.1016/j.ad.2016.05.009.
  29. Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016;128(21-22):791–795. doi:10.1007/s00508-016-1111-9.
  30. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027.
  31. Ferreira BI, Abreu JL, Reis JP, Figueiredo AM. Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol. 2016;9(6):36–43. PMID: 27386050.
  32. Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487-495. doi: 10.1080/09546634.2017.1395800.
  33. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis. J Crohns Colitis. 2019 Aug 30. pii: jjz152. doi: 10.1093/ecco-jcc/jjz152.
  34. Shalom G, Dreiher J, Cohen A. Psoriasis and obstructive sleep apnea. Int J Dermatol. 2016 Nov;55(11):e579-e584. doi: 10.1111/ijd.13367.

How to Cite

Mahmood, A. N., & Saeed, M. Y. (2020). Extracutaneous manifestations of adult psoriatic patients attending Dermatology Teaching Center in Slemani, Iraq. Bali Medical Journal, 9(1), 121–124. https://doi.org/10.15562/bmj.v9i1.1766
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
30

Share

Search Panel

Aween Nawzad Mahmood
Google Scholar
Pubmed
BMJ Journal

Mohammad Yousif Saeed
Google Scholar
Pubmed
BMJ Journal